$ATHE· SEC filing ·

ATHE Reports Positive FDA Feedback on ATH434 Phase 3 CMC Alignment, End-of-Phase 2 Meeting Targets Mid-2026

Alterity Therapeutics Limited American Depositary Shares · Now $4.02

-2.2% in 7d after detection

Post-detection moves

1h
1d
-0.9%
3d
-1.7%
7d
-2.2%
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS